Pristiq (Desvenlafaxine Succinate) Patent Expiration, LOE Window & CMS Spending

Pristiq (Desvenlafaxine Succinate) by Pfizer: FDA Orange Book core substance LOE 2027-07-05, 10 AB generics, $19.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN021992 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-07-05
Last Listed Patent or Exclusivity Date2027-07-05
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$19.0M
2024 Medicare Part D Spend$6.1M
2024 Medicaid Spend$12.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.